The stock price of SK Bioscience has been showing a strong upward trend for four consecutive trading days.
SK Bioscience, which is in charge of contract manufacturing for COVID-19 vaccines, announced that its operating profit for the second quarter of this year was 66.2 billion KRW, turning profitable compared to the previous year.
There are expectations that performance will improve further in the second half of the year. Sales from the 40 million doses of the Novavax government contract are expected to begin in earnest from the second half, and there is remaining clinical momentum for its self-developed vaccine.
So, what will be the next leading stock in vaccine contract manufacturing?
The unprecedented situation of the COVID-19 pandemic is acting as a favorable opportunity for stock investment.
While almost all stocks rose last year, this year the stock prices are moving according to themes, creating a typical theme-driven market. Analysis of themes and stocks has become important.
Large-cap stocks that led the market last year are trapped in a box range, while the KOSPI and KOSDAQ indices continue to trend upward, so it is still premature to leave the stock market.
In this difficult market where theme and stock analysis bring profits rather than economic fundamentals, investing alone carries considerable risk.
With ‘lagging investment’ that follows the rapidly changing market one step late, it is easy to worry alone while others make profits.
A wise choice for successful investment! Go to YC Investment Group homepage ▶Click◀
Let’s focus on YC Investment Group under YCIon Co., Ltd., which is achieving great results in the theme-driven market.
How about sharing their investment know-how, which shows high trust and performance with fairness and transparency as their motto?
Customized total solutions for individual investors including growth value stocks, short-term/swing trading, themes/issues, and overseas stocks.
Stock codes: SK Bioscience / Gukjeon Pharmaceutical / Quantamatrix / Finetek / Haesung Optics
※ This content is unrelated to the editorial direction of Asia Economy, and all responsibility lies with the information provider.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.



